Puma Biotechnology trades quietly in New York
Puma Biotechnology shares rose 0.3% to $7.01 on Thursday, trailing a 1.1% gain in the SPDR S&P Biotech ETF. The company last updated investors May 7, raising 2026 revenue guidance to $222–$229 million and net income to $16–$19 million. First-quarter revenue fell to $44.8 million, with a net loss of $3.8 million. Outstanding debt was paid off May 4.
